Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma

摘要

Panobinostat represents the first oral pan-histone deace-tylase (HDAC) inhibitor approved in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM) patients who had received at least two prior regimens including bortezomib and an immunomodulatory drug. The authorization was based on the results from the phase 3 trial PANORAMA 1 showing a significant longer median PFS (12.0 vs. 8.1 months, p<.0001) in patients receiving three-drug combination compared to those treated with placebo, bortezomib and dexamethasone [1]. Histone deacetylase inhibition, blocking the deacetylation of both histone and nonhistone proteins, causes transcriptional and protein activity changes eventually resulting in cell cycle arrest and apoptosis of myeloma cells [2].